Increasing specialized infrastructures and multidisciplinary applied research capacityPriority pathogens causing pandemics and emerging health risks. Focus on diagnostics, vaccines and therapeutics, while addressing critical gaps that slow down biomanufacturing.
Supporting training and development to strengthen the pipeline of qualified researchers and talentAttract and develop highly-qualified personnel, such as students, post-docs, early-career researchers and industry research, engineering and biomanufacturing technicians trained in Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP).
Accelerating the transition from promising research results to commercially-viable processes and productsStrengthen the receptor capacity of public and private developers of vaccines, therapeutics and diagnostics; support the creation of intellectual property in Canada; and increase the capacity of institutions to work in collaboration with companies including those
supported by the Strategic Innovatation Fund. 
